Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care
Mean Differences in Mortality and Thromboembolic Event Rates by Study and rFVIIa Indication
This figure includes indications with two or more comparative studies: intracranial hemorrhage (ICH)*, body trauma (Trauma), brain trauma (TBI), liver transplantation (LvrTx), and adult cardiac surgery (AdCS). Each circle represents a study; larger circles correspond to larger studies; shaded circles represent studies on treatment use of rFVIIa, and white circles represent studies on prophylactic use of rFVIIa. The mean differences in event rates for the direct (patient-centered) outcomes of total mortality and thromboembolic events are plotted for each comparative study and according to each rFVIIa indication using circle charts, with the area of each circle approximating the total sample size of its respective study.
The figures show mean differences in mortality and thromboembolic event rates, respectively, for each comparative study and according to each rFVIIa indication.
*ICH = intracranial hemorrhage here—although in rest of report “ICH” indicates a subset of intracranial hemorrhage, namely intracerebral hemorrhage.
- Yank V, Tuohy CV, Logan AC, et al. Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care, Comparative Effectiveness Review 21 (Prepared by Stanford–UCSF Evidence-based Practice Center under Contract No. 290-02-0017). Rockville, MD: Agency for Healthcare Research and Quality; May 2010. AHRQ Publication No. 10-EHC030-EF.
Your slide tray is being processed.